NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

HIV藥市場:全球產業趨勢,佔有率,規模,成長,機會及預測(2021∼2026年)

HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版商 IMARC Services Private Limited 商品編碼 999710
出版日期 內容資訊 英文 108 Pages
商品交期: 2-3個工作天內
價格
HIV藥市場:全球產業趨勢,佔有率,規模,成長,機會及預測(2021∼2026年) HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
出版日期: 2021年04月12日內容資訊: 英文 108 Pages
簡介

人類免疫力缺乏病毒(HIV)是慢且性威脅生命的疾病,透過血液和血液接觸和性接觸有人傳人感染的可能性。幾年來,在全球HIV疾病的擴大高漲,給予HIV藥需求正面的影響。HIV藥有助於防止HIV的增生,減少HIV感染的風險。全球HIV藥市場2020年達到了264億美元。

促進全球HIV藥市場成長的主要原因,是HIV的盛行率與其診斷增加等。還有市場上,也受到為了推廣對傳播原因,症狀,及治療相關意識政府舉措的強化的影響。再加上成本效益高,品牌藥化學性相同的學名藥的引進,是推動HIV藥的需求的另一個要素。預計全球HIV藥市場今後5年將顯示緩慢的成長。

本報告提供HIV藥市場相關調查,市場概要,以及各類藥物,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 範圍與調查手法

第3章 摘要整理

第4章 簡介

第5章 全球HIV藥市場

  • 市場概要
  • 市場效能
  • COVID-19的影響
  • 價格分析
  • 各類藥物的市場區隔
  • 各流通管道的市場區隔
  • 各地區的市場區隔
  • SWOT分析
    • 概要
    • 優勢
    • 弱點
    • 市場機會
    • 威脅
  • 價值鏈分析
    • 概要
    • 研究開發
    • 原料採購
    • 製造
    • 行銷
    • 分佈
    • 最終用途
  • 波特五力分析
    • 概要
    • 買方議價能力
    • 供給企業談判力
    • 競爭
    • 新加入業者的威脅
    • 替代品的威脅

第6章 市場區隔,各類藥物

  • 核苷逆轉錄酵素抑制劑
  • 多級組合產品
  • 蛋白分解酵素抑制劑
  • HIV整合酶鏈轉移抑制劑
  • 非核苷逆轉錄酵素抑制劑
  • 侵入抑制劑-CCR5輔助受體拮抗劑
  • 融合抑制劑以及其他

第7章 市場區隔,各流通管道

  • 醫院藥局
  • 零售藥局
  • 線上藥局
  • 其他

第8章 市場區隔,各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 南美

第9章 HIV藥的製造流程

  • 產品概要
  • 原料的必要條件
  • 製造流程
  • 主要的成功和風險因素

第10章 競爭情形

  • 市場結構
  • 各主要參與者市場區隔
  • 主要參與者的簡介
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • ViiV Healthcare
    • AbbVie
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Cipla Limited
    • Daiichi Sankyo
    • Emcure
    • Hetero Drugs
    • Mylan
目錄
Product Code: SR1020B96_Report

Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission. According to the latest report by IMARC Group, titled "HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026", the global HIV drugs market reached a value of US$ 26.4 Billion in 2020.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, IMARC Group expects the global HIV drugs market to exhibit moderate growth during the next five years.

Market Summary:

Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.

On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.

Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.

The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.

This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.

Key Questions Answered in This Report:

  • 1. What was the global HIV drugs market size in 2020?
  • 2. What will be the global HIV drugs market outlook during the forecast period (2021-2026)?
  • 3. What are the global HIV drugs market drivers?
  • 4. What are the major trends in the global HIV drugs market?
  • 5. What is the impact of COVID-19 on the global HIV drugs market?
  • 6. What is the global HIV drugs market breakup by class?
  • 7. What is the global HIV drugs market breakup by distribution channel?
  • 8. What are the major regions in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global HIV Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Price Analysis
  • 5.5 Market Breakup by Drug Class
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Overview
    • 5.10.2 Research and Development
    • 5.10.3 Raw Material Procurement
    • 5.10.4 Manufacturing
    • 5.10.5 Marketing
    • 5.10.6 Distribution
    • 5.10.7 End-Use
  • 5.11 Porters Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

  • 6.1 Nucleoside Reverse Transcriptase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Multi-Class Combination Products
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protease Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 HIV Integrase Strand Transfer Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Fusion Inhibitors and Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Raw Material Requirements
  • 9.3 Manufacturing Process
  • 9.4 Key Success and Risk Factors

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Boehringer Ingelheim International GmbH
    • 10.3.2 Merck & Co., Inc.
    • 10.3.3 ViiV Healthcare
    • 10.3.4 AbbVie
    • 10.3.5 F. Hoffmann-La Roche Ltd.
    • 10.3.6 Teva Pharmaceutical Industries Ltd.
    • 10.3.7 Bristol-Myers Squibb
    • 10.3.8 Gilead Sciences, Inc.
    • 10.3.9 Johnson & Johnson
    • 10.3.10 Cipla Limited
    • 10.3.11 Daiichi Sankyo
    • 10.3.12 Emcure
    • 10.3.13 Hetero Drugs
    • 10.3.14 Mylan

List of Figures

  • Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2020
  • Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2020
  • Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 7: Global: HIV Drugs Industry: SWOT Analysis
  • Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
  • Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
  • Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2015 & 2020
  • Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2021-2026
  • Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2015 & 2020
  • Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2021-2026
  • Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2015 & 2020
  • Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2021-2026
  • Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2015 & 2020
  • Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2021-2026
  • Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
  • Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

  • Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 5: HIV Drugs Manufacturing: Raw Material Requirements
  • Table 6: Global: HIV Drugs Market: Competitive Structure
  • Table 7: Global: HIV Drugs Market: Key Players